Stocks · News reference

Kiniksa Pharmaceuticals International shares are trading higher after the company reported better-than-expected Q2 financial results and raised its FY26 sales guidance above estimates.

Jul 28, 2026, 1:19 PMBenzinga Newsdesk

Read original source More stocks news

Reference details

Connected markets

Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.

Source: benzinga
Observed: Jul 28, 2026, 1:19 PM
Checked: Jul 28, 2026, 1:19 PM
Cadence: Captured once, then retained as an archive reference
Status: fresh

Keep reading

BenzingaJul 30, 2026, 6:42 PMBenzinga Newsdesk
Goldman Sachs Maintains Buy on Kiniksa Pharmaceuticals, Raises Price Target to $90
Read original at benzinga
KNSA
BenzingaJul 29, 2026, 6:31 PMBenzinga Newsdesk
JP Morgan Maintains Overweight on Kiniksa Pharmaceuticals, Raises Price Target to $107
Read original at benzinga
KNSA
BenzingaJul 29, 2026, 5:45 PMBenzinga Newsdesk
Canaccord Genuity Maintains Buy on Kiniksa Pharmaceuticals, Raises Price Target to $98
Read original at benzinga
KNSA
BenzingaJul 29, 2026, 4:53 PMBenzinga Newsdesk
Wedbush Maintains Outperform on Kiniksa Pharmaceuticals, Raises Price Target to $99
Read original at benzinga
KNSA